Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484951 · ClinicalTrials.gov registry record · Phase 4
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
A Phase 4 study of Glaucoma, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT01484951: Completed Phase 4 study of Glaucoma, sponsored by Alcon Research.
NCT01484951 is a Phase 4 study of Glaucoma that has completed, run by Alcon Research. The registered enrollment target is 74 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01484951, a Phase 4 study of Glaucoma, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.
Primary Outcome
As measured at baseline and final visit with Goldmann applanation tonometry. The outcome measure was pre-specified for Timolol 0.5% only participants.
Conditions Studied
Interventions
- DRUG Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
What the finished NCT01484951 record still lists
NCT01484951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Brinzolamide 1% and timolol 0.5% fixed combination eye drops is the first listed.
NCT01484951 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01484951 about?
NCT01484951 is a clinical study titled "AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure". The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.
What is the current status of trial NCT01484951?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2011-05. Estimated completion is 2012-03.
What conditions does trial NCT01484951 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT01484951?
The interventions under investigation include: Brinzolamide 1% and timolol 0.5% fixed combination eye drops (DRUG).
Who is sponsoring clinical trial NCT01484951?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01484951 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01484951's enrollment target sits among peer trials
74 52nd of 92 higher than 41 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia